INTISARI

Invasive diseases terdiri dari pneumonia, sepsis, dan meningitis yang disebabkan salah satunya oleh bakteri *Streptococcus pneumonia* (pneumokokus). Setiap tahunnya, kasus kematian pneumonia pada bayi dan balita di Indonesia selalu berada di peringkat atas. Dengan bertambahnya angka kejadian *invasive diseases* setiap tahun maka akan bertambah juga beban ekonomi yang akan dikeluarkan. Penelitian ini bertujuan untuk mengetahui biaya pengobatan *invasive diseases* yang meliputi *direct medical cost, direct nonmedical cost,* dan *indirect cost*, serta perbandingan *direct medical cost* dengan tarif INA-CBG's berdasarkan Permenkes RI Nomor 64 tahun 2016 pada pasien anak rawat inap di RSUD Panembahan Senopati Bantul.

Jenis penelitian ini adalah observasional dengan rancangan penelitian *cross sectional* menurut perspektif sosietal. Metode pengambilan data dilakukan secara prospektif dengan melakukan wawancara kepada orangtua pasien menggunakan kuesioner. Pengambilan data juga menggunakan data rekam medik dan data biaya pengobatan pasien *invasive diseases* rawat inap yang memenuhi kriteria inklusi. Analisis data menggunakan metode analisis statistik deskriptif dengan jumlah pasien 48 orang pneumonia dan 4 orang sepsis. Perbandingan *direct medical cost* dengan tarif INA-CBG's berdasarkan Permenkes RI Nomor 64 tahun 2016 menggunakan uji statistik *independent t test* untuk data normal dan uji statistik *mann-whitney* untuk data tidak normal.

Total *cost of illness* pasien *invasive diseases* yang meliputi *direct medical cost*, *direct nonmedical cost,* dan *indirect cost* adalah Rp164.631.963 dengan rata-rata sebesar Rp3.165.999 ± 1.008.489. Komponen terbesar pada *direct medical cost* adalah biaya obat dan alat kesehatan. Untuk perbandingan dengan tarif INA-CBG's, analisis yang diperoleh *p value* 0,000 untuk pasien pneumonia. Dapat disimpulkan bahwa *direct medical cost* dan tarif INA-CBG's memiliki perbedaan yang signifikan dengan tarif INA-CBG's lebih besar daripada biaya riil.

Kata kunci: *invasive diseases,* pneumonia, sepsis, *cost of illness*, INA-CBG's

ABSTRACT

Invasive diseases consist of pneumonia, sepsis, and meningitis which are caused by Streptococcus pneumonia (pneumococcus) bacterium. Every year, the death of infants and toddlers caused by pneumonia has always ranked at the top in Indonesia. As the incidence of invasive diseases increases each year, it will also increase the economic burden that will be issued. This study aims to determine the cost of invasive diseases treatment which includes direct medical cost, direct nonmedical cost, and indirect cost, and direct medical cost comparison with INA-CBG's fare based on Permenkes RI No. 64 year 2016 on pediatric inpatients at RSUD Panembahan Senopati Bantul.

The type of this research is observational with cross sectional study design according to societal perspective. The data collection method had been done prospectively by interviewing the parents of the patients using questionnaires. Medical record and cost of treatment of invasive diseases inpatient data fulfilling the inclusion criteria were also used to collect data. The data had been analyzed using descriptive statistic analysis method with 48 patients with pneumonia and 4 patients with sepsis. The comparison of direct medical cost with INA-CBG's fare based on Permenkes RI No. 64 year 2016 were analyzed using independent t test statistical test for normal data and mann-whitney statistical test for abnormal data.

The total cost of illness of invasive diseases including direct medical cost, direct non medical cost, and indirect cost is Rp164,631,963 with average is Rp3,165.999 ± 1,008.489. The largest component is direct medical cost, mainly the cost of drugs and medical devices. For comparison with INA-CBG's fare, the analysis obtained p value 0,000 for patients with pneumonia. It can be concluded that direct medical cost and INA-CBG's fare have significant differences with INA-CBG's fare is greater than the real cost.

Keywords: *invasive diseases*, pneumonia, sepsis, *cost of illness*, INA-CBG's